ClinicalTrials.gg
CompletedNCT03310411Updated Nov 27, 2019Results posted

A Study of Lasmiditan When Given With Sumatriptan in Healthy Participants

A Phase 1 interventional study of Lasmiditan and Sumatriptan in Healthy, sponsored by Eli Lilly and Company. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-11-27.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The purpose of this study is to assess whether taking lasmiditan and sumatriptan together will have any additional effects on heart rate and blood pressure compared to taking lasmiditan and sumatriptan individually. This study will also look at the amount of study drug that gets into the blood stream and how long it takes the body to get rid of it when these two drugs are taken together.

This study will last about 21 days, not including the screening. Participants will spend 16 days/15 nights in the clinical research unit (CRU) followed by follow-up. Screening is required within 28 days prior to the start of the study.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Eli Lilly and Company is the lead sponsor of 2,111 studies on the registry; 155 are open to participants now.

Of its 540 completed or terminated interventional studies of FDA-regulated products, 358 (66%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Are overtly healthy males or females, as determined by medical history and physical examination
  • Have a of 19.0 to 35.0 kilograms per meter squared (kg/m²) inclusive

Exclusion criteria

Exclusion Criteria:

  • Have known allergies to Lasmiditan, Sumatriptan, related compounds, or any components of the formulations of Lasmiditan and Sumatriptan
  • Have a history of, or (ECG) findings of, bradycardia, heart block, tachy or brady arrhythmias
  • Have a history, signs, or symptoms of arrhythmia or Wolff Parkinson White syndrome that could affect the participant's safety
  • Have an estimated (eGFR) of less than (\<) 60 milliliter per minute (mL/min) per 1.73 m²
  • Have a resting systolic blood pressure (SBP) greater than (>) 135 millimeters of mercury (mmHg) and diastolic blood pressure (DBP) >85 mmHg at screening
  • Have a supine pulse rate (PR) of \<50 or >90 beats per minute (bpm) at screening
  • Have a history, signs, or symptoms of vasospastic coronary artery disease
  • Have known or ongoing neuropsychiatric disorders (for example, manic depressive illness, schizophrenia, depression) considered as clinically significant by the investigator
  • Use of monoamine oxidase-A inhibitors and other drugs associated with serotonin within the 3 months prior to the first dosing occasion
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    Lasmiditan + Sumatriptan (A)

    Single oral dose of 200 milligram (mg) lasmiditan tablet and single oral dose of 100 mg sumatriptan tablet in one of four treatment periods.

    Drug: Lasmiditan · Drug: Sumatriptan

  • Experimental
    Lasmiditan + Placebo (B)

    Single oral dose of 200 mg lasmiditan tablet and single oral dose of placebo tablet in one of four treatment periods.

    Drug: Lasmiditan · Drug: Placebo for Sumatriptan

  • Active comparator
    Sumatriptan + Placebo (C)

    Single oral dose of 100 mg sumatriptan tablet and single oral dose of placebo tablet in one of four treatment periods.

    Drug: Sumatriptan · Drug: Placebo for Lasmiditan

  • Placebo comparator
    Placebo + Placebo (D)

    Oral doses of placebo tablets in one of four treatment periods.

    Drug: Placebo for Lasmiditan · Drug: Placebo for Sumatriptan

Interventions

  • Administered orally

    Also known as: LY573144

  • Administered orally

  • DrugPlacebo for Lasmiditan

    Administered orally

  • DrugPlacebo for Sumatriptan

    Administered orally

06

What researchers measure

Primary outcomes

  1. Pharmacodynamics (PD): Change From Baseline in Mean 24-hour Systolic Blood Pressure (SBP)

    Systolic Blood Pressure (SBP) was measured by using a 24-hour Ambulatory Blood Pressure Monitoring (ABPM) device attached to the participant's nondominant arm. Ambulatory blood pressure measurements were recorded every 20 minutes during the daytime (0700 to 2200 hours) and every 30 minutes during the nighttime hours (2200 to 0700), as preprogrammed into the device. For statistical analyses, diurnal hours were defined as 0800 to 2100 and nocturnal hours were defined as 0000 to 0600. Least squares (LS) mean peak changes from baseline were calculated using a linear mixed-effects model with baseline, treatment, period, and sequence as fixed effects and participant as a random effect.

    Time frame: Baseline (Day 1), Day 2

Secondary outcomes

  1. Pharmacokinetics (PK): Maximum Observed Concentration (Cmax) of Lasmiditan and Sumatriptan

    PK: Cmax of Lasmiditan and Sumatriptan was evaluated.

    Time frame: Lasmiditan: Predose, 0.5, 1, 1.5,2, 2.5, 3, 4, 6, 8, 12 , 24 ,36 and 48 hours(h) postdose; Sumatriptan: Predose, 0.5, 1, 1.5,2, 2.5, 3, 4, 6, 8, 12 and 24 h postdose

  2. Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC[0 ∞]) of Lasmiditan and Sumatriptan

    PK: AUC(0 ∞) of Lasmiditan and Sumatriptan was evaluated.

    Time frame: Lasmiditan: Predose, 0.5, 1, 1.5,2, 2.5, 3, 4, 6, 8, 12, 24 ,36 and 48 h postdose; Sumatriptan: Predose, 0.5, 1, 1.5,2, 2.5, 3, 4, 6, 8, 12 and 24 h postdose

07

Results

Posted Nov 27, 2019

Participant flow

Period 1
Participant flow — Period 1
MilestoneSequence 1Sequence 2Sequence 3Sequence 4
Started10101010
Received at least 1 dose of study drug10101010
Completed1010109
Not completed0001
Withdrew: Adverse event0001
Period 2
Participant flow — Period 2
MilestoneSequence 1Sequence 2Sequence 3Sequence 4
Started1010109
Completed1010109
Not completed0000
Period 3
Participant flow — Period 3
MilestoneSequence 1Sequence 2Sequence 3Sequence 4
Started1010109
Completed1010109
Not completed0000
Period Title: Period 4
Participant flow — Period Title: Period 4
MilestoneSequence 1Sequence 2Sequence 3Sequence 4
Started1010109
Completed1010109
Not completed0000

Outcome measures

PrimaryPharmacodynamics (PD): Change From Baseline in Mean 24-hour Systolic Blood Pressure (SBP)

Systolic Blood Pressure (SBP) was measured by using a 24-hour Ambulatory Blood Pressure Monitoring (ABPM) device attached to the participant's nondominant arm. Ambulatory blood pressure measurements were recorded every 20 minutes during the daytime (0700 to 2200 hours) and every 30 minutes during the nighttime hours (2200 to 0700), as preprogrammed into the device. For statistical analyses, diurnal hours were defined as 0800 to 2100 and nocturnal hours were defined as 0000 to 0600. Least squares (LS) mean peak changes from baseline were calculated using a linear mixed-effects model with baseline, treatment, period, and sequence as fixed effects and participant as a random effect.

Time frame:
Baseline (Day 1), Day 2
Reported as:
Least squares mean · Millimeters of mercury (mmHg)
Pharmacodynamics (PD): Change From Baseline in Mean 24-hour Systolic Blood Pressure (SBP)
Millimeters of mercury (mmHg)200 mg Lasmiditan + 100 mg Sumatriptan (A):200 mg Lasmiditan + Placebo (B)100 mg Sumatriptan + Placebo (C)Placebo + Placebo (D)
Pharmacodynamics (PD): Change From Baseline in Mean 24-hour Systolic Blood Pressure (SBP)13.81 (11.83 to 15.79)12.17 (10.47 to 13.87)13.63 (11.65 to 15.61)11.42 (9.74 to 13.09)
SecondaryPharmacokinetics (PK): Maximum Observed Concentration (Cmax) of Lasmiditan and Sumatriptan

PK: Cmax of Lasmiditan and Sumatriptan was evaluated.

Time frame:
Lasmiditan: Predose, 0.5, 1, 1.5,2, 2.5, 3, 4, 6, 8, 12 , 24 ,36 and 48 hours(h) postdose; Sumatriptan: Predose, 0.5, 1, 1.5,2, 2.5, 3, 4, 6, 8, 12 and 24 h postdose
Reported as:
Geometric mean · nanogram per milliliter (ng/mL)
Pharmacokinetics (PK): Maximum Observed Concentration (Cmax) of Lasmiditan and Sumatriptan
nanogram per milliliter (ng/mL)200 mg Lasmiditan + 100 mg Sumatriptan (A):Analyte: Lasmiditan200 mg Lasmiditan + Placebo (B): Analyte: Lasmiditan200 mg Lasmiditan +100 mg Sumatriptan (A):Analyte: Sumatriptan100 mg Sumatriptan + Placebo (C): Analyte: Sumatriptan
Pharmacokinetics (PK): Maximum Observed Concentration (Cmax) of Lasmiditan and Sumatriptan304 ± 39328 ± 3256.8 ± 3650.7 ± 42
SecondaryPharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC[0 ∞]) of Lasmiditan and Sumatriptan

PK: AUC(0 ∞) of Lasmiditan and Sumatriptan was evaluated.

Time frame:
Lasmiditan: Predose, 0.5, 1, 1.5,2, 2.5, 3, 4, 6, 8, 12, 24 ,36 and 48 h postdose; Sumatriptan: Predose, 0.5, 1, 1.5,2, 2.5, 3, 4, 6, 8, 12 and 24 h postdose
Reported as:
Geometric mean · nanogram*hour per milliliter (ng*hr/mL)
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC[0 ∞]) of Lasmiditan and Sumatriptan
nanogram*hour per milliliter (ng*hr/mL)200mg Lasmiditan + 100mg Sumatriptan (A): Analyte: Lasmiditan200 mg Lasmiditan + Placebo (B): Analyte: Lasmiditan200 mg Lasmiditan +100 mg Sumatriptan (A):Analyte: Sumatriptan100 mg Sumatriptan + Placebo (C): Analyte: Sumatriptan
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC[0 ∞]) of Lasmiditan and Sumatriptan2110 ± 372170 ± 33253 ± 28240 ± 29

Adverse events

Collected over Up To 36 Days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
200 mg Lasmiditan + 100 mg Sumatriptan (A)0/39 (0%)0/39 (0%)4/39 (10.3%)
200 mg Lasmiditan + Placebo (B)0/39 (0%)0/39 (0%)7/39 (17.9%)
100 mg Sumatriptan + Placebo (C)0/39 (0%)0/39 (0%)3/39 (7.7%)
Placebo + Placebo (D)0/40 (0%)0/40 (0%)1/40 (2.5%)
Most frequent other events
Most frequent other events
Event200 mg Lasmiditan + 100 mg Sumatriptan (A)200 mg Lasmiditan + Placebo (B)100 mg Sumatriptan + Placebo (C)Placebo + Placebo (D)
DizzinessNervous system disorders3/395/391/390/40
Upper respiratory tract infectionInfections and infestations0/392/391/390/40
HeadacheNervous system disorders2/390/392/391/40

Baseline characteristics

All enrolled participants who received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)Overall
Mean40.1 ± 12.5
Sex: Female, Male
Sex: Female, Male(Participants)Overall
Female15
Male25
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Overall
Hispanic or Latino19
Not Hispanic or Latino21
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Overall
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American16
White23
More than one race0
Unknown or Not Reported1
Region of Enrollment
Region of Enrollment(Participants)Overall
United States40
08

Study locations

1 site
  • Covance Daytona Beach
    Daytona Beach, Florida 32117, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2017 to primary completion in Dec 2017, 2 months.

Results were first posted in Nov 2019, 1 year 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 11, 2017
First posted
Oct 16, 2017
StartActual
Oct 17, 2017
Primary completionActual
Dec 23, 2017
CompletionActual
Dec 23, 2017
Results first posted
Nov 27, 2019
Last update
Nov 27, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 27, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03310411
Responsible party
Sponsor
First posted
Oct 16, 2017
Start date
Oct 17, 2017
Primary completion
Dec 23, 2017
Completion
Dec 23, 2017
Results posted
Nov 27, 2019
Last update
Nov 27, 2019

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Lasmiditan · Sumatriptan

Start the discussion